Omniox: Funding, Investors & Team (Sep 2026)
Omniox is a biopharmaceutical company developing new medicines for hypoxic diseases. Hypoxia, defined as insufficient levels of oxygen in tissues, is known to trigger or impact a range of serious illnesses and conditions including many cancers, cardiovascular diseases, and trauma. At the center of Omniox’ work is a protein-based platform technology (H-NOX), that is engineered to reverse hypoxic disease states by delivering oxygen or nitric oxide preferentially to hypoxic tissues.
Omniox has raised $24.1M across 1 funding round on record, the most recent an undisclosed round of $24.1M announced in Mar 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Omniox Company Profile and Key Stats
Latest funding round on record: Mar 2026.
Omniox Funding Rounds
Omniox Founders and Leadership Team
Contact details for the Omniox team: 1 has a LinkedIn profile.
Start 14-day free trial →Omniox Funding Compared to Other Biotechnology Startups
Omniox's latest round of $24.1M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Omniox in Biotechnology and San Francisco
Companies Similar to Omniox
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Omniox Funding FAQs
What does Omniox do?
Omniox is a biopharmaceutical company developing new medicines for hypoxic diseases. Hypoxia, defined as insufficient levels of oxygen in tissues, is known to trigger or impact a range of serious illnesses and conditions including many cancers, cardiovascular diseases, and trauma. At the center of Omniox’ work is a protein-based platform technology (H-NOX), that is engineered to reverse hypoxic disease states by delivering oxygen or nitric oxide preferentially to hypoxic tissues.
How much funding has Omniox raised?
Omniox has raised $24.1M across 1 round on record. The most recent is an undisclosed round of $24.1M announced in Mar 2026.
When did Omniox last raise funding?
Omniox's most recent funding round on record is an undisclosed round of $24.1M, announced in Mar 2026.
Who founded Omniox?
FundedIQ lists Jonathan Winger (Founder) at Omniox.
Where is Omniox headquartered?
Omniox is based in San Francisco, California, United States.
How many employees does Omniox have?
Omniox is in the 1-10 employee band.
How does Omniox's funding compare to other Biotechnology startups?
Omniox's latest round of $24.1M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Omniox Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Omniox is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.